Drug Trial Radar · NCT06238687
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Nov 8, 2023
Primary completion
Jun 6, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Tasly Pharmaceutical Group Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Sutro Biopharma, Inc.
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity, and preliminary efficacy of STRO-002 in patients with advanced malignant solid tumors.
Conditions
- Neoplasm Malignant
Interventions
STRO-002Biological
STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT AssessmentTime frame: From Day1 to Day21 after first dose of STRO-002
- AE AssessmentTime frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002
- AUCTime frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.
- CmaxTime frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.
- Half life (t1/2)Time frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.
- Overall response rate (ORR)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
- Determine the recommended phase II dose (RP2D)Time frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.